News
Researchers at UT Arlington have discovered a key enzyme, IDO1, that when blocked, helps immune cells regain their ability to properly process cholesterol—something that breaks down during ...
21h
InvestorsHub on MSNRocket Pharmaceuticals Shares Gain on FDA Green Light for Gene Therapy Targeting Heart FailureShares of Rocket Pharmaceuticals Inc (NASDAQ:RCKT) advanced 2.4% after the company announced that the U.S. Food and Drug ...
Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with AMI.
Unlike β-blockers, ivabradine does not modify myocardial contractility and intracardiac conduction, even in patients with heart failure with reduced ejection fraction. 183 In 2015, ivabradine was ...
The pathophysiology of heart failure is complex, but mitochondrial dysfunction is an emerging therapeutic target to improve cardiac function. In this Consensus Statement, insights into the ...
Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Novo Nordisk has recently completed a clinical study titled ...
Studies of the epidemiology of heart failure in the general population can inform assessments of disease burden, research, public health policy and health system care delivery. We performed a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results